During dose escalation phases, nausea may be more intense and last longer
Participants: The rapid expansion of GLP-1 receptor agonists has created unprecedented opportunities and challenges across the healthcare ecosystem, transforming treatment paradigms for diabetes, obesity, and potentially other conditions
The contents do not represent the views of the US Department of Veterans Affairs or the US government
Regular physical activity stimulates bowel motility
Obesity, currently defined as a body mass index (BMI) of 30 kg/m 2 or greater, affects 800 million people worldwide [1]
A critical review indicates that while GLP-1 receptor agonists do promote weight loss, the numbers in real-world settings are modest compared to the transformation narrative so widely circulated